X-shaped DNA potentiates therapeutic efficacy in colitis-associated colon cancer through dual activation of TLR9 and inflammasomes

Molecular Cancer

Volumn 14, Issue 1, 2015, Pages

  Koo, Jung Eun ^a   Shin, Seung Won ^b   Um, Soong Ho ^b   Lee, Joo Young ^a  

^a The Catholic University of Korea   (South Korea)

^b Sungkyunkwan University   (South Korea)

Author keywords

Caspase 1; Colon cancer; Dendritic cells; Immune adjuvant; Immunostimulatory DNA; Pattern recognition receptor

Indexed keywords

AZOXYMETHANE; DEXTRAN SULFATE; DNA; DOXORUBICIN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; MITOGEN ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; XL DNA; XS DNA; ANTINEOPLASTIC AGENT; CYTOKINE; IMMUNOLOGIC FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW DERIVED DENDRITIC CELL; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; COLITIS; COLITIS ASSOCIATED COLON CANCER; COLON CANCER; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; ENDOCYTOSIS; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC TRANSFECTION; HEK293 CELL LINE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; IMMUNOSTIMULATION; IN VIVO STUDY; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION; TH1 CELL; ANIMAL; BONE MARROW CELL; CELL DIFFERENTIATION; CHEMISTRY; COLONIC NEOPLASMS; COMPLICATION; CONFORMATION; CYTOLOGY; CYTOSOL; DENDRITIC CELL; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; CELL DIFFERENTIATION; COLITIS; COLONIC NEOPLASMS; CYTOKINES; CYTOSOL; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; DNA; DOXORUBICIN; ENDOCYTOSIS; HEK293 CELLS; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMASOMES; LYMPHOCYTE ACTIVATION; MICE; NUCLEIC ACID CONFORMATION; TH1 CELLS; TOLL-LIKE RECEPTOR 9; TREATMENT OUTCOME;

EID: 84929119032     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/s12943-015-0369-2     Document Type: Article

References (33)

1. Zeier M, Hartschuh W, Wiesel M, Lehnert T, Ritz E. Malignancy after renal transplantation. Am J Kidney Dis. 2002;39(1):e5.1-e5.12.
2. Challis GB, Stam HJ. The spontaneous regression of cancer. A review of cases from 1900 to 1987. Acta Oncol. 1990;29(5):545-50.
3. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373-84.
4. Jeong E, Lee JY. Intrinsic and extrinsic regulation of innate immune receptors. Yonsei Med J. 2011;52(3):379-92.
5. Lee JY, Zhao L, Hwang DH. Modulation of pattern recognition receptor-mediated inflammation and risk of chronic diseases by dietary fatty acids. Nutr Rev. 2010;68(1):38-61.
6. Hou W, Zhang Q, Yan Z, Chen R, Zeh Iii HJ, Kang R et al. Strange attractors: DAMPs and autophagy link tumor cell death and immunity. Cell Death Dis. 2013;4:e966.
7. Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature. 2009;461(7261):282-6.
8. Gross JA, Callas E, Allison JP. Identification and distribution of the costimulatory receptor CD28 in the mouse. J Immunol. 1992;149(2):380-8.
9. Jin B, Sun T, Yu XH, Yang YX, Yeo AE. The effects of TLR activation on T-cell development and differentiation. Clin Dev Immunol. 2012;2012:836485.
10. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov. 2007;6(12):975-90.
11. Um SH, Lee JB, Park N, Kwon SY, Umbach CC, Luo D. Enzyme-catalysed assembly of DNA hydrogel. Nat Mater. 2006;5(10):797-801.
12. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol. 2004;4(4):249-58.
13. Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene. 2008;27(2):161-7.
14. Ren T, Wen ZK, Liu ZM, Qian C, Liang YJ, Jin ML, et al. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients. Cancer Invest. 2008;26(5):448-55.
15. Roberts TL, Dunn JA, Terry TD, Jennings MP, Hume DA, Sweet MJ, et al. Differences in macrophage activation by bacterial DNA and CpG-containing oligonucleotides. J Immunol. 2005;175(6):3569-76.
16. Nishikawa M, Matono M, Rattanakiat S, Matsuoka N, Takakura Y. Enhanced immunostimulatory activity of oligodeoxynucleotides by Y-shape formation. Immunology. 2008;124(2):247-55.
17. Mizuno Y, Naoi T, Nishikawa M, Rattanakiat S, Hamaguchi N, Hashida M et al. Simultaneous delivery of doxorubicin and immunostimulatory CpG motif to tumors using a plasmid DNA/doxorubicin complex in mice. J Control Release. 2010;141(2):252-9.
18. Nishikawa M, Mizuno Y, Mohri K, Matsuoka N, Rattanakiat S, Takahashi Y et al. Biodegradable CpG DNA hydrogels for sustained delivery of doxorubicin and immunostimulatory signals in tumor-bearing mice. Biomaterials. 2011;32(2):488-94
19. Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol. 2004;5(2):190-8.
20. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med. 2009;15(10):1170-8.
21. Jung J. Human tumor xenograft models for preclinical assessment of anticancer drug development. Toxicological Res. 2014;30(1):1-5.
22. Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol. 2009;27:83-117.
23. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991-8.
24. Lee M, Park CS, Lee YR, Im SA, Song S, Lee CK. Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells. Arch Pharm Res. 2014;37(9):1234-40.
25. Speiser DE, Lienard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005;115(3):739-46.
26. Jahrsdorfer B, Muhlenhoff L, Blackwell SE, Wagner M, Poeck H, Hartmann E, et al. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res. 2005;11(4):1490-9.
27. Koo JE, Hong HJ, Dearth A, Kobayashi KS, Koh YS. Intracellular invasion of Orientia tsutsugamushi activates inflammasome in asc-dependent manner. PLoS One. 2012;7(6):e39042.
28. Kim SY, Koo JE, Seo YJ, Tyagi N, Jeong E, Choi J, et al. Suppression of Toll-like receptor 4 activation by caffeic acid phenethyl ester is mediated by interference of LPS binding to MD2. Br J Pharmacol. 2013;168(8):1933-45.
29. Jeong E, Koo JE, Yeon SH, Kwak MK, Hwang DH, Lee JY. PPARdelta deficiency disrupts hypoxia-mediated tumorigenic potential of colon cancer cells. Mol Carcinog. 2014;53(11):926-37.
30. Joung SM, Park ZY, Rani S, Takeuchi O, Akira S, Lee JY. Akt contributes to activation of the TRIF-dependent signaling pathways of TLRs by interacting with TANK-binding kinase 1. J Immunol. 2011;186(1):499-507.
31. Kim SY, Choi YJ, Joung SM, Lee BH, Jung YS, Lee JY. Hypoxic stress up-regulates the expression of Toll-like receptor 4 in macrophages via hypoxia-inducible factor. Immunology.129(4):516-24.
32. Zaki MH, Vogel P, Malireddi RK, Body-Malapel M, Anand PK, Bertin J et al. The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis. Cancer Cell.20(5):649-60.
33. Kim T, Pazhoor S, Bao M, Zhang Z, Hanabuchi S, Facchinetti V et al. Aspartate-glutamate-alanine-histidine box motif (DEAH)/RNA helicase A helicases sense microbial DNA in human plasmacytoid dendritic cells. Proc Natl Acad Sci U S A.107(34):15181-6